Cardinal Health(US:CAH) Prnewswireยท2025-08-12 10:55Core Insights - Cardinal Health reported fourth quarter fiscal year 2025 revenues of $60.2 billion, which is relatively flat compared to the same period in fiscal year 2024. Excluding the impact of a customer contract expiration, revenue increased by 21% [1][12] - The company achieved GAAP operating earnings of $428 million and GAAP diluted earnings per share (EPS) of $1.00 for the fourth quarter. Non-GAAP operating earnings rose by 19% to $719 million, with non-GAAP diluted EPS increasing by 13% to $2.08 [1][12] - For the full fiscal year 2025, revenues totaled $222.6 billion, a 2% decrease from fiscal year 2024. However, revenue increased by 18% when excluding the impact of the customer contract expiration [2][12] - Cardinal Health's CEO highlighted the operational strength across all five operating segments, which experienced double-digit profit growth, indicating effective execution of the company's growth strategy [3][12] Financial Performance - Fourth quarter fiscal year 2025 summary: - Revenue: $60.2 billion (Q4 FY24: $59.9 billion) - GAAP operating earnings: $428 million (Q4 FY24: $401 million, 7% increase) - Non-GAAP operating earnings: $719 million (Q4 FY24: $605 million, 19% increase) - Non-GAAP diluted EPS: $2.08 (Q4 FY24: $1.84, 13% increase) [4][12] - Full year fiscal year 2025 summary: - Revenue: $222.6 billion (FY24: $226.8 billion, 2% decrease) - GAAP operating earnings: $2.3 billion (FY24: $1.2 billion, 83% increase) - Non-GAAP operating earnings: $2.8 billion (FY24: $2.4 billion, 15% increase) - Non-GAAP diluted EPS: $8.24 (FY24: $7.53, 9% increase) [2][4] Segment Performance - Pharmaceutical and Specialty Solutions segment: - Q4 FY25 revenue: $55.4 billion (Q4 FY24: $55.6 billion) - Segment profit increased by 11% to $535 million in Q4 FY25 [5][6] - Global Medical Products and Distribution segment: - Q4 FY25 revenue: $3.2 billion (Q4 FY24: $3.1 billion, 3% increase) - Segment profit increased by 49% to $70 million in Q4 FY25 [7][8] - Other segment: - Q4 FY25 revenue: $1.6 billion (Q4 FY24: $1.2 billion, 37% increase) - Segment profit increased by 44% to $160 million in Q4 FY25 [9][10] Future Outlook - Cardinal Health raised its fiscal year 2026 outlook for non-GAAP diluted EPS to a range of $9.30 to $9.50, reflecting a growth of 13% to 15% [10][12] - The company anticipates revenue growth of 11% to 13% in the Pharmaceutical and Specialty Solutions segment and 2% to 4% in the Global Medical Products and Distribution segment for fiscal year 2026 [11][12]